Information Provided By: 
Fly News Breaks for May 15, 2017
JAZZ
May 15, 2017 | 07:18 EDT
RBC Capital analyst Randall Stanicky started coverage of Jazz with a $210 price target and an Outperform rating. The analyst says that the stock poses little risk while the company's growth is poised to accelerate. He thinks that the launch of the company's Vyxeos drug in 2H17 can spark additional "earnings momentum," and he calls the stock's valuation "compelling."
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
